SCOTTSDALE, Ariz., April 19 /PRNewswire/ -- It has been requested by the U.S. FDA (Food & Drug Administration) and the newly formed Department of Counter Terrorism (DCT) that ImmuneRegen BioSciences, Inc. considers establishing a response team to effectively react in the event of an act of bio-terrorism and/or chemical disaster. This request was made in the minutes delivered to the senior management team during their FDA meeting in Washington for Acute Radiation Sickness (ARS) on March 12th 2004. “For our company, this request serves as confirmation that the governing body of drug treatments sees promise that a potential treatment or prophylaxis for this indication can be available,” says Michael Wilhelm. “This is a great step for the company.”
The company will soon be initiating a study to determine the most effective form of administration of its proprietary compound “Homspera” for this indication. For ARS, the company currently administers “Homspera” via aerosol, and we are determining if there is greater efficacy and ease of use through a direct muscle injection.
The team will be lead by the company’s acting CSO & Founder, Dr. Mark Witten, and ImmuneRegen is determining the other members best fit for the team. We expect to have the team established and all other necessary implementation in place shortly after we complete the upcoming administration/delivery study.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (BULLETIN BOARD: IRBO) , is a biotechnology company engaged in the research and development of applications utilizing modified Substance P, a naturally occurring immunomodulator. Derived from homeostatic substance P, the company has named their proprietary compound “Homspera.” The Company’s initial focus is on the continuing development of Homspera for various applications for use in improving pulmonary function and stimulating the human immune system. For more information, please visit the company’s website at http://www.immuneregen.com/.
About Homspera
ImmuneRegen’s patents and continued substance P research are derived from discoveries made during research funded by the Air Force Office of Scientific Research in the early 1990s. During this research, Dr. Witten and his associates observed that the exposure of animals to jet fuels resulted in pathological changes in the lung and immune systems of those exposed. It was also observed that such exposure resulted in depletion of substance P from the lungs of the animals. These studies further showed that the administration of substance P may help prevent and reverse the effects of jet fuel exposure in the lungs, as well as protect and regenerate the immune system. The immune findings led to early research on the treatment of exposure to acute radiation and on the possible reversal of lung damage caused by ARDS and cigarette smoke.
Statements about the Company’s future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. The Company’s actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research collaborations, clinical trials and product development programs, the evaluation of potential opportunities, the level of corporate expenditures, capital market conditions, and others set forth in the Company’s SEC filings.
ImmuneRegen BioSciences, Inc.
CONTACT: media, Michelle Derden of Spelling Communications,+1-310-477-9500, mderden@spellcom.com; or investors, Tony Schor ofInvestorAwareness, +1-847-945-2222, investawar@aol.com; both for ImmuneRegenBioSciences, Inc.
Web site: http://www.immuneregen.com/
